Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Drug Approvals › Pediatrics
Explore the latest data on pediatrics drug approvals. Our analytics platform processes thousands of data points daily to deliver reliable market intelligence. Our methodology combines automated data collection with expert curation to ensure high-quality, reliable information. Each data point is verified against multiple sources before publication.
Data accuracy is our top priority. We employ automated quality checks and manual review processes to maintain the highest standards. If you notice any discrepancies, please report them through our feedback form. Professional analysts frequently cite our data in market reports and strategic presentations. Our methodology has been validated by independent auditors and meets industry-standard accuracy requirements.
This page is part of the FDA News data platform, which offers comprehensive coverage across related categories. Navigate using the links above to explore other sections.
| Drug Name | Manufacturer | Approval Date | Indication | Type |
|---|---|---|---|---|
| Pedixumab | PharmaCo A | Mar 2026 | Advanced pediatrics | Biologic |
| Peditinib | PharmaCo B | Jan 2026 | Relapsed pediatrics | Small molecule |
| Pedilizumab | PharmaCo C | Nov 2025 | Moderate pediatrics | Monoclonal Ab |
| Pedistat | PharmaCo D | Sep 2025 | Chronic pediatrics | Oral |
| Pediparin | PharmaCo E | Jul 2025 | Acute pediatrics | Injectable |
Data updated continuously. Last refresh: May 11, 2026 14:30 UTC.
